SEOUL, Korea, Nov. 28, 2016 /PRNewswire/ -- Nature Cell Co., Ltd.(Nature Cell ) (CEO, Dr. Jeongchan Ra), a leading biotechnology company, announce sAstroStem's approval for Phase I andPhase II clinical trial s for treatment of Alzheimer's disease by the U .S . Food and Drug Administration (FDA) on November 23. AstroStem is a therapeutic agent for adult stem cells that collects about 10g of fat from the patient's own abdominal subcutaneous tissue and separates only pure stem cells into a finished product, which is repeatedly administered intravenously to the patient. Production of the approved clinical trial materials will be done by the RBio Biostar Stem Cell Research Institute (Biostar), which has been developing technology for dementia reduction for more than 10 years. Dr. Jeongchan Ra of Biostar has collaborated with professor Yoohun Suh, a global brain research leader, to isolate the stem cell, which was cultivated with patented technology as an animal model for Alzheimer's disease. The results were published inPLoS One, a respected scientific journal, and recognized worldwide. The approval of the US FDA is significant milestoneand is the first time in the world that a commercial clinical trial in which autologous adipose-derived stem cells are cultured and repeatedly administered intravenously has been approved. Biostar's technology for repeated intravenous administration of stem cells has already been applied more than 3,000 times in the past year to patients with autoimmune diseases who have been approved by Japan's Ministry of Health and Welfare.